Two-Dose Novavax Vaccine Protects Against SARS-CoV-2 Infection
TUESDAY, July 6, 2021 -- A two-dose regimen of the NVX-CoV2373 (Novavax) recombinant nanoparticle vaccine against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has efficacy of 89.7 percent in adults, according to a study published...
Source: Drugs.com - Pharma News - Category: Pharmaceuticals Source Type: news
More News: Coronavirus | COVID-19 | Nanotechnology | Pharmaceuticals | Respiratory Medicine | SARS | Study | Vaccines